Last reviewed · How we verify
Brexanolone Injection [Zulresso]
Brexanolone is a synthetic neuroactive steroid that acts as a positive allosteric modulator of GABA-A receptors to enhance inhibitory neurotransmission in the brain.
Brexanolone is a synthetic neuroactive steroid that acts as a positive allosteric modulator of GABA-A receptors to enhance inhibitory neurotransmission in the brain. Used for Postpartum depression in adult women.
At a glance
| Generic name | Brexanolone Injection [Zulresso] |
|---|---|
| Also known as | Zulresso |
| Sponsor | Donald Jeffrey Newport |
| Drug class | Neuroactive steroid; GABA-A receptor positive allosteric modulator |
| Target | GABA-A receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Neurology |
| Phase | FDA-approved |
Mechanism of action
Brexanolone is the synthetic form of allopregnanolone, an endogenous neurosteroid metabolite of progesterone. It binds to and potentiates GABA-A receptors, increasing chloride channel conductance and neuronal hyperpolarization, thereby enhancing GABAergic inhibitory signaling. This mechanism is thought to restore neurochemical balance in postpartum depression, where allopregnanolone levels are dysregulated.
Approved indications
- Postpartum depression in adult women
Common side effects
- Sedation
- Dizziness
- Somnolence
- Headache
- Syncope
- Loss of consciousness
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Brexanolone Injection [Zulresso] CI brief — competitive landscape report
- Brexanolone Injection [Zulresso] updates RSS · CI watch RSS
- Donald Jeffrey Newport portfolio CI